Whereas the CALGB 40603 trial, first reported in 2015, showed higher pathologic complete response rates among TNBC patients treated with carboplatin (5), the subsequent GEPAR-SIXTO (published in 2017) (6) and INFORM (published in 2019) (7) trials demonstrated no improvement when a platinum was added to, or substituted for, standard chemotherapy for BRCA1/2 PV carriers with early stage breast cancer. This evidence concerns the gene BRCA1 and breast cancer.